SUBSCRIBE Blog with us: BLOGbiotech

Breaking News

• Email
• Print
• Share
• More News

May 18 2007, 6:18 AM EST

Cytokinetics Announces Clinical Trials Data to Be Presented at the 2007 Annual Meeting of the American Society of Clinical Oncology

MARKETWIRE

May 18, 2007 SOUTH SAN FRANCISCO, CA MARKET WIRE

Cytokinetics, Incorporated (NASDAQ: CYTK) announced today that three abstracts summarizing data from clinical trials relating to its oncology program will be presented at the 2007 Annual Meeting of the American Society of Clinical Oncology (ASCO) in Chicago, IL, June 1-5, 2007. Two of these abstracts relate to clinical trials evaluating ispinesib that were sponsored by GlaxoSmithKline (GSK) or the National Cancer Institute (NCI). The third abstract relates to a clinical trial sponsored by Cytokinetics evaluating SB-743921.

Ispinesib and SB-743921 are both novel, chemically distinct, small molecule inhibitors of kinesin spindle protein (KSP), a mitotic kinesin essential for proper cell division. Both drug candidates have arisen from a broad strategic collaboration between Cytokinetics and GSK to discover, develop and commercialize novel small molecule therapeutics targeting human mitotic kinesins for applications in the treatment of cancer and other diseases.

Poster Presentations and Publications of Abstracts at ASCO

The following abstracts will be presented at ASCO or published in the ASCO 2007 Annual Meeting Proceedings and will be available through the ASCO website (www.asco.org):

Poster Presentation:

Abstract #5562: A Phase II, Open-Label Study of Ispinesib (SB-715992) in Patients with Platinum/Taxane Refractory or Resistant Relapsed Ovarian Cancer. (Oral presentation by Mark S Shahin, Abington Memorial Hospital, Abington, PA, on Saturday, June 2, 2007, Gynecologic Cancer; S Hall A2, Board #S5, 2:00 PM - 6:00 PM).

Publication of Abstract: (Abstract will be published in the ASCO 2007 Annual Meeting Proceedings)

Abstract #15573: University of Chicago Consortium Phase II Study of Ispinesib (SB-715992) in Patients with Advanced Renal Cell Carcinoma. K. W. Beekman, University of Michigan, Ann Arbor, MI.

Abstract #18516: A Phase I-II Study to Assess the Safety, Pharmacokinetics, and Potential Efficacy of Intravenous SB-743921 on Days 1 and 15 of a 28-day Cycle in Patients with Non-Hodgkin Lymphoma. A. Goy, Hackensack University Medical Center, Hackensack, NJ.

Clinical Trials of Ispinesib

Ispinesib has been the subject of a broad Phase II clinical trials program under the sponsorship of GlaxoSmithKline (GSK) and is also being developed in collaboration with the National Cancer Institute (NCI). GSK has sponsored three Phase II clinical trials, one evaluating ispinesib as second- or third-line treatment for patients with locally advanced or metastatic breast cancer, one evaluating ispinesib as second-line treatment for patients with non-small cell lung cancer, and one evaluating ispinesib as second-line treatment for patients with advanced ovarian cancer. Enrollment in all of these studies has been closed. To date, clinical activity with ispinesib has been observed in breast cancer and in non-small cell lung cancer, with the more robust clinical activity observed in a Phase II clinical trial evaluating ispinesib in the treatment of metastatic breast cancer patients that have failed treatment with taxanes and anthracyclines. GSK has informed Cytokinetics that final data are expected from the breast cancer clinical trial in the first half of 2007.

In addition, GSK has sponsored three dose-escalating Phase Ib clinical trials. Each of these clinical trials was designed to evaluate the safety, tolerability and pharmacokinetics of ispinesib in combination with a leading anti-cancer therapeutic, one in combination with carboplatin, the second in combination with capecitabine, and the third in combination with docetaxel. The clinical trial eval

• Email
• Print
• Share
• More News

CAREER CENTER

WEBINARS

PODCASTS

MOST POPULAR